Comparative Pharmacology
Head-to-head clinical analysis: METHOTREXATE LPF versus SIKLOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOTREXATE LPF versus SIKLOS.
METHOTREXATE LPF vs SIKLOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the synthesis of tetrahydrofolate and subsequently thymidylate and purine synthesis. This inhibits DNA synthesis, repair, and cellular replication. In low-dose regimens, it has anti-inflammatory and immunomodulatory effects through adenosine release and inhibition of cytokine production.
Hydroxyurea inhibits ribonucleotide reductase, reducing the synthesis of deoxyribonucleotides and thereby decreasing DNA synthesis. In sickle cell disease, it increases fetal hemoglobin (HbF) levels, which inhibits sickling of red blood cells.
7.5 to 25 mg orally once weekly for rheumatoid arthritis; for psoriasis, 10 to 25 mg orally once weekly. Intravenous dosing varies by indication; for high-dose methotrexate (e.g., osteosarcoma), 8 to 12 g/m² IV over 4 hours.
100–200 mg/kg/day orally in two divided doses, not to exceed 200 mg/kg/day.
None Documented
None Documented
Terminal half-life 3-10 hours for low doses, 8-15 hours for high doses; prolonged to 12-24 hours in renal impairment due to delayed clearance.
Terminal elimination half-life is 2-5 hours in adults; shorter in children (1-2 hours). Clinical context: requires thrice-daily dosing to maintain therapeutic concentrations; longer half-life in hepatic impairment (up to 10 hours).
Primarily renal (80-90% unchanged via glomerular filtration and active tubular secretion); small amount biliary/fecal (<10%).
Primarily hepatic metabolism via CYP3A4; renal excretion of metabolites accounts for approximately 70-80% of the dose, with <1% excreted unchanged in urine. Fecal excretion is minor (<5%).
Category D/X
Category C
Antimetabolite
Antimetabolite